



Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993 -- Subcutaneous Drug Development & Delivery Consortium, Inc.

Notice is hereby given that, on December 21, 2022, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. ("the Act"), Subcutaneous Drug Development & Delivery Consortium, Inc. ("Subcutaneous Drug Development & Delivery Consortium, Inc.") has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Biogen Inc., Cambridge, MA; C.H. Boehringer Sohn AG & Co. KG, Ridgefield, CT; Kaléo, Inc., Richmond, VA; KORU Medical Systems, Mahwah, NJ; NEMERA La Verpilliere SAS, La Verpilliere, FRANCE; and Comera Life Sciences, Woburn, MA, have been added as parties to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and Subcutaneous Drug Development & Delivery

Consortium, Inc. intends to file additional written notifications disclosing all changes in membership.

On October 26, 2020, Subcutaneous Drug Development & Delivery Consortium, Inc. filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the *Federal Register* pursuant to Section 6(b) of the Act on December 3, 2020 (85 FR 78148).

The last notification was filed with the Department on April 25, 2022. A notice was published in the *Federal Register* pursuant to Section 6(b) of the Act on May 13, 2022 (87 FR 29381).

Suzanne Morris,

*Deputy Director of Civil
Enforcement Operations,
Antitrust Division.*